Selection of patients for resection of hepatic metastases: Improved detection of extrahepatic disease with FDG PET

Radiographics

Volumn 21, Issue SPEC.ISS., 2001, Pages

  Zealley, Ian A ^a   Skehan, Stephen J ^a   Rawlinson, John ^a   Coates, Geoffrey ^a   Nahmias, Claude ^a   Somers, Sat ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

Fluorine, radioactive; Liver neoplasms; Liver neoplasms, metastases, 761.3327; PET, 761.12163

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

COLORECTAL TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; IMAGE PROCESSING; LIVER TUMOR; METASTASIS; METHODOLOGY; PATHOLOGY; PATIENT SELECTION; REVIEW; SCINTISCANNING; TUMOR RECURRENCE;

COLORECTAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LIVER NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035489084     PISSN: 02715333     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiographics.21.suppl_1.g01oc05s55     Document Type: Article

References (30)

1. 18F) fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996; 131:703-707.
2. Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997; 38:1196-1201.
3. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al._ Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998; 206:755-760.
4. Flamen P, Stroobarts S, Van Cutsem E, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999; 17:894-901.
5. 18F) fluorodeoxy-glucose in management of recurrent colorectal cancer. Arch Surg 1999; 134:503-511.
6. 18F-FDG positron emission tomography scanning in selection of patients for resection of hepatic colorectal metastases. Am J Surg 1999; 178:282-287.
7. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41:1177-1189.
8. Fuhrman GM, Curley SA, Hohn DS, Roh MS. Improved survival after resection of colorectal liver metastases. Ann Surg Oncol 1995;2:537-541.
9. Jenkins LT, Millikan KW, Bines SD, Staren ED, Doolas A. Hepatic resection for metastatic colorectal cancer. Am Surg 1997; 63:605-610.
10. Vauthey JN. Liver imaging: a surgeon's perspective. Radiol Clin North Am 1998; 36:445-457.
11. Ekberg H, Tranberg KG, Andersson R, et al. Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 1987; 11:541-547.
12. Holm A, Bradley E, Aldrete J. Hepatic resection of metastases from colorectal carcinoma: mortality, morbidity and pattern of recurrence. Ann Surg 1989; 209:428-434.
13. Strasberg SM, Dehdashti F, Siegel BA, Drebin JA, Linehan D. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal cancer: a prospective database study. Ann Surg 2001; 233:293-299.
14. Greenway B. Hepatic metastases from colorectal cancer: resection or not? Br J Surg 1988; 75:513-519.
15. Sugarbaker PH. Surgical management decision making for large bowel cancer metastatic to the liver. Radiology 1990; 174:621-626.
16. Paley MR, Ros PR. Hepatic metastases. Radiol Clin North Am 1998; 36:349-363.
17. Fortner JG, Silva JS, Golbey RB, Cox EB, Maclean BJ. Multivariate analysis of a personal series of 247 consecutive patients with liver metastases from colorectal cancer. I. Treatment by hepatic resection. Ann Surg 1984; 199:306-316.
18. Steele GJ, Ravikumar TS. Resection of hepatic metastases from colorectal cancer: biologic perspective. Ann Surg 1989; 210:127-138.
19. Erasmus JJ, McAdams HP, Patz EF Jr, Goodman PC, Coleman RE. Thoracic FDG PET: state of the art. RadioGraphics 1998; 18:5-20.
20. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997; 4:613-620.
21. Liefers GJ, Cleton-Jansen AM, van de Velde CJH, et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998; 339:223-228.
22. Whiteford MH, Whiteford HM, Ogunbiyi OA, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000; 43:759-770.
23. Berger KL, Nicholson SA, Dehdashti F, Siegel BA. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. AJR 2000; 174:1005-1008.
24. Skehan SJ, Brown AL, Thompson M, Young JEM, Coates G, Nahmias C. Imaging features of primary and recurrent esophageal cancer at FDG PET. RadioGraphics 2000; 20:713-723.
25. Wahl RL. To AC or not to AC: that is the question. J Nucl Med 1999; 40:2025-2028.
26. Farquhar TH, Llacer J, Hoh CK, et al. ROC and localization ROC analyses of lesion detection in whole-body FDG PET: effects of acquisition mode, attenuation correction and reconstruction algorithm. J Nucl Med 1999; 40:2043-2052.
27. Bleckmann C, Dose J, Bohuslavizki KH, et al. Effect of attenuation correction on lesion detectability in FDG PET of breast cancer. J Nucl Med 1999; 40:2021-2024.
28. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. RadioGraphics 1999; 19:61-77.
29. Gordon BA, Flanagan FL, Dehdashti F. Whole-body positron emission tomography: normal variations, pitfalls, and technical considerations. AJR 1997; 169:1675-1680.
30. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998; 16:1075-1084.